Kyntra Bio (KYNB) Share-based Compensation (2014 - 2026)

Kyntra Bio has disclosed Share-based Compensation across 13 years of filings, most recently posting $984000.0 for Q2 2026.

• In Q2 2026, Share-based Compensation fell 47.46% year-over-year to $984000.0; the TTM figure through Jun 2026 stood at $4.0 million (down 68.34% YoY), while the FY2025 annual figure was $6.6 million, down 73.92% from the prior year.
• Share-based Compensation came in at $984000.0 for Q2 2026 at Kyntra Bio, down from $1.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $17.2 million in Q1 2022 to a low of $178000.0 in Q4 2024.
• Average Share-based Compensation over 5 years is $8.3 million, with a median of $8.7 million recorded in 2024.
• Year-over-year, Share-based Compensation slumped 98.09% in 2024 and surged 567.98% in 2025.
• Over 5 years, Share-based Compensation stood at $16.2 million in 2022, then sank by 42.7% to $9.3 million in 2023, then tumbled by 98.09% to $178000.0 in 2024, then surged by 567.98% to $1.2 million in 2025, then declined by 17.24% to $984000.0 in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $984000.0 in Q2 2026, $1.2 million in Q1 2026, and $1.2 million in Q4 2025.